sábado, 14 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 27, 2025

BioNTech (BNTX) Q3 2025 Earnings Call Transcript

View original at nasdaq.com
BioNTech (BNTX) Q3 2025 Earnings Call Transcript Image source: The Motley Fool. Date Nov. 3, 2025 at 12:46 p.m…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We expect to report a loss for the 2025 financial year as we continue to invest in our transition to become a fully integrated commercial oncology company

    80% confidence

  • First potential launches of Pumitamig expected before end of decade (pre-2030)

    80% confidence

  • T-cell response breadth correlates with activity in iNeST therapy; immune cell PD-L1 matters; signal observed in TMB-low patients

    80% confidence

  • US COVID-19 vaccination rate at ~20% is in line with expectations

    80% confidence

  • COVID-19 vaccine business has stable market share and pricing with lower volumes vs prior year, performing within expectations

    80% confidence

  • First pivotal combination regimen decisions for Pumitamig expected based on data over next year

    80% confidence

  • Management emphasized rigorous financial discipline and focus on long-term sustainable growth

    80% confidence

  • BioNTech is positioned as a fully integrated AI-tech bio company with AI capabilities addressing inter-patient heterogeneity and intra-tumor variability

    80% confidence

Data points we hold from this source

BioNTech SE · eps-0.12 EUR
BioNTech SE · net income-29 million_EUR
BioNTech SE · rd expenses565 million_EUR
BioNTech SE · sga expenses148 million_EUR
BioNTech SE · cost of sales148 million_EUR

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com
BioNTech (BNTX) Q3 2025 Earnings Call Transcript — Source | Via News | es.VIA.NEWS